Dr. Joel Vandersluis, M.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Years since graduation
- 37
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 534
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
OH license 35-06-4098-V
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Miami Valley Hospital Dayton, OH
- Kettering Health Dayton Dayton, OH
- Kettering Health Main Campus Kettering, OH
- Soin Medical Center Beaver Creek, OH
- Kettering Health Miamisburg Miamisburg, OH
Medical groups
- Neurology Diagnostics Inc (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 534
- Services billed
- 16,451
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Needle measurement of electrical activity in arm or leg muscles, complete study | 470 | 237 |
| Established patient office or other outpatient visit, 30-39 minutes | 375 | 282 |
| Established patient office or other outpatient visit, 20-29 minutes | 221 | 200 |
| Ultrasound of both sides of head and neck blood flow | 202 | 201 |
| Nerve conduction, 9-10 studies | 174 | 171 |
| Measurement of brain wave activity (eeg), awake and asleep | 164 | 162 |
| New patient office or other outpatient visit, 60-74 minutes | 141 | 141 |
| Complete ultrasound of within the brain blood flow | 87 | 87 |
| Nerve conduction, 11-12 studies | 79 | 78 |
| New patient office or other outpatient visit, 45-59 minutes | 67 | 67 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Donepezil Hcl Other prescribers in Dayton, OH | 735 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Dayton, OH | 240 |
| Gabapentin Other prescribers in Dayton, OH | 218 |
| Primidone Other prescribers in Dayton, OH | 172 |
| Levetiracetam Other prescribers in Dayton, OH | 120 |
| Lamotrigine Other prescribers in Dayton, OH | 114 |
| Memantine Hcl Other prescribers in Dayton, OH | 92 |
| Amitriptyline Hcl Other prescribers in Dayton, OH | 44 |
| Lorazepam Other prescribers in Dayton, OH | 37 |
| Baclofen Other prescribers in Dayton, OH | 37 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 27 companies reported 148 payments worth $4,305 in total to this clinician.
| Ipsen Innovation | $1,406 |
|---|---|
| Vanda Pharmaceuticals Inc. | $343 |
| EMD Serono, Inc. | $292 |
| Neurocrine Biosciences, Inc. | $237 |
| Celgene Corporation | $211 |
| Teva Pharmaceuticals USA, Inc. | $197 |
| Pfizer Inc. | $172 |
| Lilly USA, LLC | $152 |
| Food and Beverage | $3,173 |
|---|---|
| Travel and Lodging | $1,073 |
| Education | $58.49 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ipsen Innovation Jun 18, 2025 | Travel and Lodging travel to Minneapolis, MN · in-kind | $837 |
| Ipsen Innovation Jun 17, 2025 | Travel and Lodging travel to Minneapolis, MN · in-kind | $236 |
| Teva Pharmaceuticals USA, Inc. Apr 23, 2025 | Education in-kind | $58.49 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 16 industry-funded studies in 2025, from 7 companies. The companies reported $1,229,671 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (Targe…
E.r. Squibb & Sons, L.l.c. - Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy
Eli Lilly and Company · Completed · NCT06568042 - A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment …
Novartis Pharmaceuticals Corporation - A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Eli Lilly and Company · Active, not recruiting · NCT05026866 - AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls …
Novartis Pharmaceuticals Corporation - A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
Eli Lilly and Company · Completed · NCT05463731 - A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Scle…
Amgen Inc. - A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Eli Lilly and Company · Active, not recruiting · NCT04437511 - A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
Ipsen Innovation · Active, not recruiting · NCT06625060 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimer…
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.